“Neumentix stands out in the nootropic market because of its demonstrated efficacy and safety,” said Kim Colletti, Global Product Manager for Kemin Human Nutrition and Health. “It’s been studied in three clinical trials and has also recently earned GRAS (generally recognized as safe) status. Data from this Makoto study gives supplement manufacturers the flexibility to formulate with Neumentix in a variety of growing categories, for both cognitive and athletic performance.”
The Makoto Arena is a novel device used to measure reaction time to stimuli, mental focus and hand-eye, foot-eye coordination. Healthy, active subjects ages 18 to 50 years old were supplemented with 900 mg Neumentix or placebo at breakfast for 90 days. Those supplemented with Neumentix showed improved reaction time after seven days, and improved focus and agility after 30 days. These results indicate Neumentix benefits athletic performance by supporting cognitive performance in a sports setting.
The global nootropic market is expected to grow at a compound annual growth rate (CAGR) of 17.9 percent by 2024, while the United States sports nutrition market is expected to grow at a CAGR of 8.1 percent by 2022.1,2 Both markets are driven by consumers’ search for more energy and productivity throughout the day.1
To learn more about Neumentix and its effects on cognitive and physical performance, visit www.neumentix.com.
About Kemin Industries
Kemin (www.kemin.com) has been dedicated to using applied science to improve the quality of life for over half a century. As a global company touching 3.5 billion people every day with its products, Kemin is committed to improving the quality, safety and efficacy of food, feed and health-related products to feed a growing population and be a resource for others in need.
Committed to feed and food safety, Kemin maintains top-of-the-line manufacturing facilities where over 500 specialty ingredients are made for humans and animals in the global feed and food industries, as well as the health, nutrition and beauty markets. The company provides product solutions and options to customers in more than 120 countries.
A privately held, family-owned and operated company, Kemin has more than 2,000 global employees and operates in 90 countries including manufacturing facilities in Belgium, Brazil, China, India, Italy, Russia, Singapore, South Africa and the United States.
- Global Nootropics Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2014 to 2024. Markets and Reports; December 2016.
- Sports Nutrition Market (Sports Food, Sports Drink & Sports Supplements): Global Industry Perspective, Comprehensive Analysis and Forecast, 2016-2022. Zion Market Research; January 2017.
Kim Colletti, Global Cognition Product Manager, Kemin Human Nutrition and Health, email@example.com, 515-559-5407
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/kemin-clinical-study-shows-promise-in-sports-and-nootropic-markets-300479139.html
SOURCE Kemin Industries